Clinical Trial Update: A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating 90-day safety of Tapentadol immediate-release versus Oxycodone immediate-release in adults with chronic pain, including osteoarthriti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthralgia
• Low Back Pain
• Osteoarthritis
• Sciatica

Drugs mentioned

• Nucynta (tapentadol)
• Oxycodone IR (oxycodone)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Osteoarthritis, Pain Intensity Assessment | Phase 3 | Status: COMPLETED